Thomas Jones, MD
Endocrinology, Diabetes & Metabolism · Macon, GANPI 1740208966
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $24,150 of the $37,701 with a category attached, or 64.1%. Tandem Diabetes Care, Inc. accounts for 62.1% of it on its own, with 52 other manufacturers making up the rest. Reporting peaked in 2021 at $20,017 and has fallen 92.4% since, to $1,512 in 2025. Among endocrinology, diabetes & metabolism clinicians in GA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 803 payments — averaging $46.95 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Tandem Diabetes Care, Inc.$23K
- Novo Nordisk$2K
- Lilly USA, LLC$2K
- Medtronic$1K
- Eli Lilly$1K
- Amgen$805
- plus $8K from 47 others
Across 194 payments — averaging $25,121 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Eli Lilly$4M
- AbbVie$406K
- Sanofi US Services Inc.$258K
- Insulet Corporation$212K
- Medtronic$38K
- Abbott$7K
- plus $1K from 2 others
What the payments were for
- Speaking & faculty fees$24,15064%
- Travel & lodging$7162%
- Food & beverage$12,51133%
- Education$2651%
- Gifts$590%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- t-slim insulin pump$20,500
- t:slim X2 insulin pump$2,651
- Minimed 770G System$1,100
- FreeStyle Lite system$200
- TEPEZZA$122
- INVOKANA$122
- RYBELSUS$114
How this compares
$37,701 in reported general payments places this provider in the 90th percentile of 222 endocrinology, diabetes & metabolism providers in Georgia.
See all endocrinology, diabetes & metabolism providers in Georgia →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 348 | $564,428 |
| JardianceEmpagliflozin | 183 | $208,981 |
| Tresiba Flextouch U-200Insulin Degludec | 112 | $127,784 |
| MounjaroTirzepatide | 67 | $84,262 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 49 | $69,254 |
| TrulicityDulaglutide | 49 | $61,187 |
| Tresiba Flextouch U-100Insulin Degludec | 87 | $55,179 |
| ForteoTeriparatide | 12 | $50,046 |
| JanuviaSitagliptin Phosphate | 51 | $46,531 |
| FarxigaDapagliflozin Propanediol | 43 | $42,988 |
| Omnipod Dash Pods (Gen 4)Insulin Pump Cart,cont Inf,bt | 17 | $31,158 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 13 | $30,115 |
| RybelsusSemaglutide | 28 | $28,463 |
| Fiasp FlextouchInsulin Aspart (Niacinamide) | 29 | $28,160 |
| SynthroidLevothyroxine Sodium | 264 | $23,786 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus, Novolog | $1,809 | $612,320423 claims |
| Lilly USA, LLCMounjaro, Trulicity, Forteo, Lyumjev, Humalog | $1,507 | $225,875207 claims |
| Boehringer IngelheimJardiance, Synjardy | $331 | $212,852196 claims |
| MerckJanuvia | $104 | $46,53151 claims |
| AstraZenecaFarxiga | $292 | $42,98843 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33, Lantus | $701 | $32,07534 claims |
| AbbVieSynthroid | $310 | $23,786264 claims |
| Johnson & JohnsonInvokana | $311 | $19,00722 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $398 | $3,549320 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 222 endocrinology, diabetes & metabolism providers in Georgia.
Other endocrinology, diabetes & metabolism in Macon
- Barry JohnsMacon$335K
- Ashwini GoreMacon$34K
- Bruce BodeAtlanta$1.5M
- David RobertsonAtlanta$1.4M
- Adeniyi OdugbesanLawrenceville$636K
- Miguel MunozMarietta$476K
- Jason BernerJasper$457K
- Dawn Smiley-ByrdTaylorsville$385K
- Jonathan OwnbyAtlanta$291K
- Ismary DecastroSavannah$169K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.